Skip to main content
. 2022 Jun 9;12:901971. doi: 10.3389/fcimb.2022.901971

Table 2.

Summary of key antimalarials, front-runner and development compounds as well as investigative hits with in vitro activity (< 5 µM) against P. falciparum mature gametocytes.

Compound IC50 (nM) Stg V Target Ref
Mefloquine (+RS) 158 80S ribosome (Plouffe et al., 2016)
ELQ-300 72 Cytochrome bc1(Qi) (Nilsen et al., 2013)
Cipargamin (KAE609) 100* PfATP4 / Na2+ homeostasis (Van Pelt-Koops et al., 2012)
KAF246 2 (Rottmann et al., 2010; Plouffe et al., 2016)
M5717 (DDD498) 9 PfEF2 / protein synthesis (Rottmann et al., 2010; Plouffe et al., 2016)
MMV390048 140 PfPI4K (Paquet et al., 2017)
AZD-0156 236 (Reader et al., 2021)
KDU691 150 (Mcnamara et al., 2013)
ML324 77 Pfjmj3 (Reader et al., 2021)
JIB-04 3630 (Matthews et al., 2020)
Methylene blue 258 Glutathione reductase (Buchholz et al., 2008; Plouffe et al., 2016)
GNF179 3 Protein secretory pathway (Plouffe et al., 2016)
Birinapant 135 Unknown (caspase 3 inhibitor) (Reader et al., 2021)
MMV1581558 130 Unknown (Adenosine A3 receptor)
MMV1580843 108 Unknown
SQ109 104 Unknown (MmpL3 in Mtb)
Epoxomicin 6.6 β2 and 5 proteasome subunits (D'Alessandro et al., 2016)

*% inhibition of gametocyte viability 500 nM.